New initiative from ISIDORe: RES4PRIOPATH for quicker identification of potential pandemic viruses

Published 18 March 2024

Founded by ISIDORe’s Joint Research Activities Programme 2023-2025, RES4PRIOPATH is An Integrated Antiviral Discovery Platform of Broad-Spectrum Small Molecule Inhibitors of Viral Targets from Priority Preparedness Pathogens.

We are thrilled to share the launch of RES4PRIOPATH, a groundbreaking consortium coordinated by MEDINA which aims to identify small molecule inhibitors for new emerging viruses flagged in genetic surveillances.

RESP4PRIOPATH is a collaborative effort that merges the capabilities of 4 European research infrastructures: EU-OPENSCREENINSTRUCT-ERICERINHA and EATRIS, through a consortium comprised by the following partners: MEDINA-EU-OPENSCREEN-ES, CCMF-EUOPENSCREEN-DE, IBBMedChem-OPENSCREEN-PAN, GUF-BMRZ, CIRMMP-CERM-Instruct-IT , CERBM-IGBMC-Instruct-FR, UH-Instruct-FI, KULCapsIt-ERINHA-BE, and Instituto de Medicina Molecular João Lobo Antunes (iMM) at EATRIS-PT. This team of experts counts on complementary skills including high-throughput screening, drug discovery, protein expression, structural biology and virology.

ISIDORe’s founding has enabled the assembly of the consortium, which will focus on developing a European platform to quickly identify antivirals for potential pandemic viruses with no therapies available. These demonstrator cases will consolidate fast-tracking workflows and preparedness tools to respond to new variants of concern of known viruses or even to new ones.

“RES4PRIOPATH is a significant milestone in our joint endeavour in the ISIDORe project – JRA programme, to combat emerging viral threats. Through the collaborative efforts of the four European research infrastructures (EU-OPENSCREEN, INSTRUCT, ERINHA and EATRIS) we’ve established a pioneering platform set to innovate antiviral discovery. With expertise spanning from (high-throughput screening), drug discovery, protein expression, structural biology and virology, our partnership is a step further in pandemic preparedness. We are especially happy to see Instituto de Medicina Molecular João Lobo Antunes (iMM) from EATRIS Portugal node, representing the forward-thinking and proactive spirit of the EATRIS community.”

– David Morrow, EATRIS Senior Scientific Programme Manager

 

David Morrow

Scientific Lead Advanced Therapies
Coordination & support office


  • Find out more about ISIDORe here.
  • Read the original press release by Fudación MEDINA here.